

# Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

## Recombinant Anti-SRP54 antibody [EPR10851(B)]

RRID:AB\_3076262

Type: Antibody

---

### Proper Citation

Abcam Cat# ab154796, RRID:AB\_3076262

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_3076262](http://antibodyregistry.org/AB_3076262)

**Proper Citation:** Abcam Cat# ab154796, RRID:AB\_3076262

**Target Antigen:** SRP54

**Host Organism:** Rabbit

**Clonality:** recombinant monoclonal

**Comments:** Applications: WB, IHC-P

**Antibody Name:** Recombinant Anti-SRP54 antibody [EPR10851(B)]

**Description:** This recombinant monoclonal targets SRP54

**Target Organism:** rat, mouse, human

**Clone ID:** EPR10851(B)

**Antibody ID:** AB\_3076262

**Vendor:** Abcam

**Catalog Number:** ab154796

**Record Creation Time:** 20231216T131808+0000

**Record Last Update:** 20260901T025910+0000

---

### Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-SRP54 antibody [EPR10851(B)].

No alerts have been found for Recombinant Anti-SRP54 antibody [EPR10851(B)].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Liu B, et al. (2025) The hexosamine biosynthetic pathway drives tumor immune evasion via translational control of PD-L1 at the elongation level. Cell reports, 44(9), 116249.

Wang X, et al. (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell, 187(18), 4890.